| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
|
Sallman, David A.
|
|
|
81 |
C |
p. 56-61
|
article
|
| 2 |
Autograft immune content and survival in non-Hodgkin’s lymphoma: A post hoc analysis
|
Porrata, Luis F.
|
|
|
81 |
C |
p. 1-9
|
article
|
| 3 |
Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells
|
Zhang, Cong-li
|
|
|
81 |
C |
p. 19-24
|
article
|
| 4 |
Compound mutations in CML—imaginary bogeyman or real arch-nemesis?
|
Yeung, David T.
|
|
|
81 |
C |
p. 102-104
|
article
|
| 5 |
Corrigendum to ’Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.’ [Leuk Res. 2016 Jul;46:61-68.]
|
Fang, Jun
|
|
|
81 |
C |
p. 107
|
article
|
| 6 |
Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44]
|
Gerds, Aaron T.
|
|
|
81 |
C |
p. 105
|
article
|
| 7 |
Corrigendum to ‘Toll-like receptors Expression and involvement in Multiple Myeloma’ [Leukemia Research 34 (2010)1545-1550]
|
Chiron, D.
|
|
|
81 |
C |
p. 106
|
article
|
| 8 |
Editorial Board
|
|
|
|
81 |
C |
p. ii
|
article
|
| 9 |
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols
|
Gascón, Pere
|
|
|
81 |
C |
p. 35-42
|
article
|
| 10 |
First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter
|
Belohlavkova, Petra
|
|
|
81 |
C |
p. 67-74
|
article
|
| 11 |
Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia
|
Wang, Yu-Hung
|
|
|
81 |
C |
p. 95-97
|
article
|
| 12 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience
|
Spunarova, Michaela
|
|
|
81 |
C |
p. 75-81
|
article
|
| 13 |
Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology
|
Zinzani, Pier Luigi
|
|
|
81 |
C |
p. 88-94
|
article
|
| 14 |
Low-level BCR-ABL1 transcripts in individuals without overt hematologic malignancy
|
Leeman-Neill, Rebecca J.
|
|
|
81 |
C |
p. 98-101
|
article
|
| 15 |
Management and outcome of 11 pregnancies in women with polycythemia vera
|
Elli, E.M.
|
|
|
81 |
C |
p. 25-26
|
article
|
| 16 |
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors
|
Largeaud, Laetitia
|
|
|
81 |
C |
p. 82-87
|
article
|
| 17 |
Publishers Note
|
|
|
|
81 |
C |
p. I
|
article
|
| 18 |
Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia
|
Moshaver, Bijan
|
|
|
81 |
C |
p. 27-34
|
article
|
| 19 |
Relevant updates in systemic mastocytosis
|
Coltoff, Alexander
|
|
|
81 |
C |
p. 10-18
|
article
|
| 20 |
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis
|
Stevens, Brett
|
|
|
81 |
C |
p. 43-49
|
article
|
| 21 |
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
|
Chen, Haiming
|
|
|
81 |
C |
p. 62-66
|
article
|
| 22 |
The role of high serum CXCL13 level in Waldenström macroglobulinemia
|
Wu, Yan-yan
|
|
|
81 |
C |
p. 50-55
|
article
|
Journal description